Ragini M. Mistry
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ragini M. Mistry has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Fabio Stossi
Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA
20 shared publications - André Catic
Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA
19 shared publications - Ergun Sahin
Huffington Center on Aging, Baylor College of Medicine, Houston, TX 77030, USA
19 shared publications - Joanne I. Hsu
Translational Biology and Molecular Medicine Graduate Program, Baylor College of Medicine
19 shared publications - Laure Maneix
Baylor College of Medicine
19 shared publications - Polina Iakova
Department of Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
19 shared publications
Latest Publications
- 5 March 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 17 (826) , eadh4475
eEF1A2 promotes PTEN-GSK3β-SCF complex-dependent degradation of Aurora kinase A and is inactivated in breast cancer
The translation elongation factor eEF1A promotes protein synthesis. Its methylation by METTL13 increases its activity, supporting tumor growth. However, in some cancers, a high abundance of eEF1A isoforms is associated with a good prognosis. Here, we found that eEF1A2 exhibited oncogenic or tumor-suppressor functions depending on its interaction with METTL13 or the phosphatase PTEN, respectively. METTL13 and PTEN competed for interaction with eEF1A2 in the same structural domain. PTEN-bound eEF1A2 promoted the ubiquitination and degradation of the mitosis-promoting Aurora kinase A in the S and G2 phases of the cell cycle. eEF1A2 bridged the interactions between the SKP1-CUL1-FBXW7 (SCF) ubiquitin ligase complex, the kinase GSK3β, and Aurora-A, thereby facilitating the phosphorylation of Aurora-A in a degron site that was recognized by FBXW7. Genetic ablation of Eef1a2 or Pten in mice resulted in a greater abundance of Aurora-A and increased cell cycling in mammary tumors, which was corroborated in breast cancer tissues from patients. Reactivating this pathway using fimepinostat, which relieves inhibitory signaling directed at PTEN and increases FBXW7 expression, combined with inhibiting Aurora-A with alisertib, suppressed breast cancer cell proliferation in culture and tumor growth in vivo. The findings demonstrate a therapeutically exploitable, tumor-suppressive role for eEF1A2 in breast cancer.
- 5 March 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 17 (826) , eadh4475
eEF1A2 promotes PTEN-GSK3β-SCF complex-dependent degradation of Aurora kinase A and is inactivated in breast cancer
The translation elongation factor eEF1A promotes protein synthesis. Its methylation by METTL13 increases its activity, supporting tumor growth. However, in some cancers, a high abundance of eEF1A isoforms is associated with a good prognosis. Here, we found that eEF1A2 exhibited oncogenic or tumor-suppressor functions depending on its interaction with METTL13 or the phosphatase PTEN, respectively. METTL13 and PTEN competed for interaction with eEF1A2 in the same structural domain. PTEN-bound eEF1A2 promoted the ubiquitination and degradation of the mitosis-promoting Aurora kinase A in the S and G2 phases of the cell cycle. eEF1A2 bridged the interactions between the SKP1-CUL1-FBXW7 (SCF) ubiquitin ligase complex, the kinase GSK3β, and Aurora-A, thereby facilitating the phosphorylation of Aurora-A in a degron site that was recognized by FBXW7. Genetic ablation of Eef1a2 or Pten in mice resulted in a greater abundance of Aurora-A and increased cell cycling in mammary tumors, which was corroborated in breast cancer tissues from patients. Reactivating this pathway using fimepinostat, which relieves inhibitory signaling directed at PTEN and increases FBXW7 expression, combined with inhibiting Aurora-A with alisertib, suppressed breast cancer cell proliferation in culture and tumor growth in vivo. The findings demonstrate a therapeutically exploitable, tumor-suppressive role for eEF1A2 in breast cancer.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 Stabilization and Chromatin Condensation
Proteasome inhibitors have become the standard of care for multiple myeloma. Blocking protein degradation particularly perturbs the homeostasis of short-lived polypeptides such as transcription factors and epigenetic regulators. To determine how proteasome inhibitors directly impact gene regulation, we performed an integrative genomics study in multiple myeloma cells. We discovered that proteasome inhibitors reduce the turnover of DNA-associated proteins and repress genes necessary for proliferation through epigenetic silencing. Specifically, proteasome inhibition results in the localized accumulation of histone deacetylase 3 (HDAC3) at defined genomic sites, which reduces H3K27 acetylation and increases chromatin condensation. The loss of active chromatin at super-enhancers critical for multiple myeloma, including the super-enhancer controlling the proto-oncogene c-MYC, reduces metabolic activity and cancer cell growth. Epigenetic silencing is attenuated by HDAC3 depletion, suggesting a tumor-suppressive element of this deacetylase in the context of proteasome inhibition. In the absence of treatment, HDAC3 is continuously removed from DNA by the ubiquitin ligase Seven in Absentia Homolog 2 (SIAH2). Overexpression of SIAH2 increases H3K27 acetylation at c-MYC–controlled genes, increases metabolic output, and accelerates cancer cell proliferation. Our studies indicate a novel therapeutic function of proteasome inhibitors in multiple myeloma by reshaping the epigenetic landscape in an HDAC3-dependent manner. As a result, blocking the proteasome effectively antagonizes c-MYC and the genes controlled by this proto-oncogene.Significance:Integrative genomics reveals that a key function of proteasome inhibitors involves limiting the activity of MYC and MYC-dependent genes through epigenetic repression.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 Stabilization and Chromatin Condensation
Proteasome inhibitors have become the standard of care for multiple myeloma. Blocking protein degradation particularly perturbs the homeostasis of short-lived polypeptides such as transcription factors and epigenetic regulators. To determine how proteasome inhibitors directly impact gene regulation, we performed an integrative genomics study in multiple myeloma cells. We discovered that proteasome inhibitors reduce the turnover of DNA-associated proteins and repress genes necessary for proliferation through epigenetic silencing. Specifically, proteasome inhibition results in the localized accumulation of histone deacetylase 3 (HDAC3) at defined genomic sites, which reduces H3K27 acetylation and increases chromatin condensation. The loss of active chromatin at super-enhancers critical for multiple myeloma, including the super-enhancer controlling the proto-oncogene c-MYC, reduces metabolic activity and cancer cell growth. Epigenetic silencing is attenuated by HDAC3 depletion, suggesting a tumor-suppressive element of this deacetylase in the context of proteasome inhibition. In the absence of treatment, HDAC3 is continuously removed from DNA by the ubiquitin ligase Seven in Absentia Homolog 2 (SIAH2). Overexpression of SIAH2 increases H3K27 acetylation at c-MYC–controlled genes, increases metabolic output, and accelerates cancer cell proliferation. Our studies indicate a novel therapeutic function of proteasome inhibitors in multiple myeloma by reshaping the epigenetic landscape in an HDAC3-dependent manner. As a result, blocking the proteasome effectively antagonizes c-MYC and the genes controlled by this proto-oncogene.Significance:Integrative genomics reveals that a key function of proteasome inhibitors involves limiting the activity of MYC and MYC-dependent genes through epigenetic repression.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 from Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 Stabilization and Chromatin Condensation
Genome-wide analysis of acute effects of proteasome inhibition on transcription and chromatin in MM cells.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 Stabilization and Chromatin Condensation
Genome-wide analysis of acute effects of proteasome inhibition on transcription and chromatin in MM cells.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S7 from Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 Stabilization and Chromatin Condensation
The SIAH2 ubiquitin ligase antagonizes HDAC3-mediated repression in MM cells.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 Stabilization and Chromatin Condensation
The SIAH2 ubiquitin ligase antagonizes HDAC3-mediated repression in MM cells.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S4 from Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 Stabilization and Chromatin Condensation
DNA site-specific stabilization of HDAC3 by proteasome inhibition in MM cells.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 Stabilization and Chromatin Condensation
DNA site-specific stabilization of HDAC3 by proteasome inhibition in MM cells.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S3 from Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 Stabilization and Chromatin Condensation
Proteasome inhibition represses cell proliferation and mitochondrial activity in MM.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 Stabilization and Chromatin Condensation
Proteasome inhibition represses cell proliferation and mitochondrial activity in MM.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S2 from Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 Stabilization and Chromatin Condensation
Proteasome inhibition down-regulates cell cycle and mitochondrial gene expression in three different MM cell lines.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 Stabilization and Chromatin Condensation
Proteasome inhibition down-regulates cell cycle and mitochondrial gene expression in three different MM cell lines.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S5 from Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 Stabilization and Chromatin Condensation
HDAC3 mediates repression of the H3K27ac mark at super-enhancers of genes relevant for MM biology following proteasome inhibition.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 Stabilization and Chromatin Condensation
HDAC3 mediates repression of the H3K27ac mark at super-enhancers of genes relevant for MM biology following proteasome inhibition.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S4 from Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 Stabilization and Chromatin Condensation
DNA site-specific stabilization of HDAC3 by proteasome inhibition in MM cells.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 Stabilization and Chromatin Condensation
DNA site-specific stabilization of HDAC3 by proteasome inhibition in MM cells.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S2 from Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 Stabilization and Chromatin Condensation
Proteasome inhibition down-regulates cell cycle and mitochondrial gene expression in three different MM cell lines.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 Stabilization and Chromatin Condensation
Proteasome inhibition down-regulates cell cycle and mitochondrial gene expression in three different MM cell lines.